Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2009

01.01.2009 | Case Report

Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report

verfasst von: Özkan Alkasi, Ivo Meinhold-Heerlein, Rania Zaki, Peter Fasching, Nicolai Maass, Walter Jonat, Matthias W. Beckmann

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Approximately 50% of patients with low-grade endometrial stromal sarcoma (ESS) develop recurrent disease including mainly metastases of pelvis and lung. A solitary pulmonary metastasis of this disease is a rare phenomenon.

Case

After initial surgical treatment in 1990, a 28-year-old female developed solitary metastases of the lung in 1998 and 1999, which were surgically removed both times. The patient was then treated with goserelin for 2 years followed by anastrozole to date. She has since been disease-free.

Conclusions

This case report emphasizes the importance of long-term follow-up and initial surgical treatment of low-grade ESS and suggests systemic hormonal therapy in case of recurrence.
Literatur
1.
Zurück zum Zitat Aubry MC, Myers JL et al (2002) Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol 26(4):440–449PubMedCrossRef Aubry MC, Myers JL et al (2002) Endometrial stromal sarcoma metastatic to the lung: a detailed analysis of 16 patients. Am J Surg Pathol 26(4):440–449PubMedCrossRef
2.
Zurück zum Zitat Balleine RL, Earls PJ et al (2004) Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. Int J Gynecol Pathol 23(2):138–144PubMedCrossRef Balleine RL, Earls PJ et al (2004) Expression of progesterone receptor A and B isoforms in low-grade endometrial stromal sarcoma. Int J Gynecol Pathol 23(2):138–144PubMedCrossRef
3.
Zurück zum Zitat Bodner K, Bodner-Adler B et al (2001) Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 81(2):160–165PubMedCrossRef Bodner K, Bodner-Adler B et al (2001) Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients. Gynecol Oncol 81(2):160–165PubMedCrossRef
4.
Zurück zum Zitat Burke C, Hickey K (2004) Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 104(5 Pt 2):1182–1184PubMed Burke C, Hickey K (2004) Treatment of endometrial stromal sarcoma with a gonadotropin-releasing hormone analogue. Obstet Gynecol 104(5 Pt 2):1182–1184PubMed
5.
Zurück zum Zitat Chu MC, Mor G et al (2003) Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90(1):170–176PubMedCrossRef Chu MC, Mor G et al (2003) Low-grade endometrial stromal sarcoma: hormonal aspects. Gynecol Oncol 90(1):170–176PubMedCrossRef
6.
Zurück zum Zitat Corpa MV, Serafini EP et al (2004) Low-grade endometrial stromal sarcoma presenting as vaginal nodule. Ann Diagn Pathol 8(5):295–298PubMedCrossRef Corpa MV, Serafini EP et al (2004) Low-grade endometrial stromal sarcoma presenting as vaginal nodule. Ann Diagn Pathol 8(5):295–298PubMedCrossRef
7.
Zurück zum Zitat Dines DE, Cortese DA et al (1973) Malignant pulmonary neoplasms predisposing to spontaneous pneumothorax. Mayo Clin Proc 48(8):541–544PubMed Dines DE, Cortese DA et al (1973) Malignant pulmonary neoplasms predisposing to spontaneous pneumothorax. Mayo Clin Proc 48(8):541–544PubMed
8.
Zurück zum Zitat Fukunaga M, Endo Y (1996) Pelvic bone involvement in low-grade endometrial stromal sarcoma with ovarian sex cord-like differentiation. Histopathology 29(4):391–393PubMedCrossRef Fukunaga M, Endo Y (1996) Pelvic bone involvement in low-grade endometrial stromal sarcoma with ovarian sex cord-like differentiation. Histopathology 29(4):391–393PubMedCrossRef
9.
Zurück zum Zitat Hendrickson MR, Tavassoli RL et al (2003) Mesenchymal tumors and related lesions. WHO classification of tumors. In: Tavassoli RL, Lyon PD, IARG Press, pp 233–249 Hendrickson MR, Tavassoli RL et al (2003) Mesenchymal tumors and related lesions. WHO classification of tumors. In: Tavassoli RL, Lyon PD, IARG Press, pp 233–249
10.
Zurück zum Zitat Itoh T, Mochizuki M et al (1997) Cystic pulmonary metastases of endometrial stromal sarcoma of the uterus, mimicking lymphangiomyomatosis: a case report with immunohistochemistry of HMB45. Pathol Int 47(10):725–729PubMedCrossRef Itoh T, Mochizuki M et al (1997) Cystic pulmonary metastases of endometrial stromal sarcoma of the uterus, mimicking lymphangiomyomatosis: a case report with immunohistochemistry of HMB45. Pathol Int 47(10):725–729PubMedCrossRef
11.
Zurück zum Zitat Jautzke G, Muller-Ruchholtz E et al (1996) Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 192(3):215–223PubMed Jautzke G, Muller-Ruchholtz E et al (1996) Immunohistological detection of estrogen and progesterone receptors in multiple and well differentiated leiomyomatous lung tumors in women with uterine leiomyomas (so-called benign metastasizing leiomyomas). A report on 5 cases. Pathol Res Pract 192(3):215–223PubMed
12.
Zurück zum Zitat Katz L, Merino MJ et al (1987) Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol 26(1):87–97PubMedCrossRef Katz L, Merino MJ et al (1987) Endometrial stromal sarcoma: a clinicopathologic study of 11 cases with determination of estrogen and progestin receptor levels in three tumors. Gynecol Oncol 26(1):87–97PubMedCrossRef
13.
Zurück zum Zitat Koss LG, Spiro RH et al (1965) Endometrial stromal sarcoma. Surg Gynecol Obstet 121:531–537PubMed Koss LG, Spiro RH et al (1965) Endometrial stromal sarcoma. Surg Gynecol Obstet 121:531–537PubMed
14.
Zurück zum Zitat Leath CA III, Huh WK et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105(3):630–634PubMedCrossRef Leath CA III, Huh WK et al (2007) A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol 105(3):630–634PubMedCrossRef
15.
Zurück zum Zitat Leunen M, Breugelmans M et al (2004) Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95(3):769–771PubMedCrossRef Leunen M, Breugelmans M et al (2004) Low-grade endometrial stromal sarcoma treated with the aromatase inhibitor letrozole. Gynecol Oncol 95(3):769–771PubMedCrossRef
16.
Zurück zum Zitat Li AJ, Giuntoli RL II et al (2005) Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 106(6):1304–1308PubMed Li AJ, Giuntoli RL II et al (2005) Ovarian preservation in stage I low-grade endometrial stromal sarcomas. Obstet Gynecol 106(6):1304–1308PubMed
17.
Zurück zum Zitat Maluf FC, Sabbatini P et al (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82(2):384–8PubMedCrossRef Maluf FC, Sabbatini P et al (2001) Endometrial stromal sarcoma: objective response to letrozole. Gynecol Oncol 82(2):384–8PubMedCrossRef
18.
Zurück zum Zitat Pink D, Lindner T et al (2006) Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101(3):464–469PubMedCrossRef Pink D, Lindner T et al (2006) Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 101(3):464–469PubMedCrossRef
19.
Zurück zum Zitat Reich O, Nogales FF et al (2005) Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 18(4):573–576PubMedCrossRef Reich O, Nogales FF et al (2005) Gonadotropin-releasing hormone receptor expression in endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 18(4):573–576PubMedCrossRef
20.
Zurück zum Zitat Reich O, Regauer S (2004) Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 17(1):104–108PubMedCrossRef Reich O, Regauer S (2004) Aromatase expression in low-grade endometrial stromal sarcomas: an immunohistochemical study. Mod Pathol 17(1):104–108PubMedCrossRef
21.
Zurück zum Zitat Reich O, Regauer S (2005) Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma. Gynecol Oncol 98(1):173–174 (author reply 174–175)PubMedCrossRef Reich O, Regauer S (2005) Hormonal treatment with aromatase inhibitors for patients with endometrial stromal sarcoma. Gynecol Oncol 98(1):173–174 (author reply 174–175)PubMedCrossRef
22.
Zurück zum Zitat Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19(4):347–352PubMedCrossRef Reich O, Regauer S (2007) Hormonal therapy of endometrial stromal sarcoma. Curr Opin Oncol 19(4):347–352PubMedCrossRef
23.
Zurück zum Zitat Reich O, Regauer S et al (2000) Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82(5):1030–1034PubMedCrossRef Reich O, Regauer S et al (2000) Expression of oestrogen and progesterone receptors in low-grade endometrial stromal sarcomas. Br J Cancer 82(5):1030–1034PubMedCrossRef
24.
Zurück zum Zitat Satoh Y, Ishikawa Y et al (2003) Pulmonary metastases from a low-grade endometrial stromal sarcoma confirmed by chromosome aberration and fluorescence in-situ hybridization approaches: a case of recurrence 13 years after hysterectomy. Virchows Arch 442(2):173–178PubMed Satoh Y, Ishikawa Y et al (2003) Pulmonary metastases from a low-grade endometrial stromal sarcoma confirmed by chromosome aberration and fluorescence in-situ hybridization approaches: a case of recurrence 13 years after hysterectomy. Virchows Arch 442(2):173–178PubMed
25.
Zurück zum Zitat Spano JP, Soria JC et al (2003) Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 20(1):87–93PubMedCrossRef Spano JP, Soria JC et al (2003) Long-term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma. Med Oncol 20(1):87–93PubMedCrossRef
26.
Zurück zum Zitat Tseng L, Tseng JK et al (1986) Endocrine aspects of human uterine sarcoma: a preliminary study. Am J Obstet Gynecol 155(1):95–101PubMed Tseng L, Tseng JK et al (1986) Endocrine aspects of human uterine sarcoma: a preliminary study. Am J Obstet Gynecol 155(1):95–101PubMed
Metadaten
Titel
Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report
verfasst von
Özkan Alkasi
Ivo Meinhold-Heerlein
Rania Zaki
Peter Fasching
Nicolai Maass
Walter Jonat
Matthias W. Beckmann
Publikationsdatum
01.01.2009
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2009
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-008-0631-6

Weitere Artikel der Ausgabe 1/2009

Archives of Gynecology and Obstetrics 1/2009 Zur Ausgabe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.